Tetrabenazine

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1828 publications

Effect of Deuterated Drugs on Safety: Insights from Pharmacovigilance Data Analysis.

Effect of Deuterated Drugs on Safety: Insights from Pharmacovigilance Data Analysis.

Journal: Biological & pharmaceutical bulletin

Published: June 21, 2026

Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: Psychopharmacology bulletin

Published: June 10, 2026

Acute Onset Extrapyramidal Symptoms With Clozapine: A Report of a Rare Case.

Acute Onset Extrapyramidal Symptoms With Clozapine: A Report of a Rare Case.

Journal: Cureus

Published: May 11, 2026

Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials.

Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials.

Journal: The Journal of clinical psychiatry

Published: May 07, 2026

Severe neurotoxicity from accidental tetrabenazine ingestion in a child, with laboratory confirmation.

Severe neurotoxicity from accidental tetrabenazine ingestion in a child, with laboratory confirmation.

Journal: Clinical toxicology (Philadelphia, Pa.)

Published: April 09, 2026

Tetrabenazine-Responsive Choreo-Ballism and Akathisia After Cardioversion and Coronary Angiography: A Case Report.

Tetrabenazine-Responsive Choreo-Ballism and Akathisia After Cardioversion and Coronary Angiography: A Case Report.

Journal: Cureus

Published: April 06, 2026

SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism for the treatment of movement and neuropsychiatric disorders.

SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism for the treatment of movement and neuropsychiatric disorders.

Journal: Frontiers in pharmacology

Published: March 06, 2026

The diagnostic value of 18F-AV-133 VMAT2 hybrid PET-MRI for cognitive impairment in Parkinson's disease

The diagnostic value of 18F-AV-133 VMAT2 hybrid PET-MRI for cognitive impairment in Parkinson's disease

Journal: Zhonghua yi xue za zhi

Published: January 26, 2026

Beyond motor symptoms: efficacy of pharmacotherapies on motor, functional, and cognitive domains in Huntington's disease - a systematic review.

Beyond motor symptoms: efficacy of pharmacotherapies on motor, functional, and cognitive domains in Huntington's disease - a systematic review.

Journal: European journal of pharmacology

Published: January 05, 2026

Self-nanonizing gelatin oleyl conjugate solid dispersions for enhanced solubility and permeability of tetrabenazine.

Self-nanonizing gelatin oleyl conjugate solid dispersions for enhanced solubility and permeability of tetrabenazine.

Journal: International journal of pharmaceutics

Published: December 27, 2025

Small Gold Nanoparticles Alleviate Huntington's Disease via Modulating p38α Mitogen-Activated Protein Kinase and Pyruvate Dehydrogenase Kinase 1.

Small Gold Nanoparticles Alleviate Huntington's Disease via Modulating p38α Mitogen-Activated Protein Kinase and Pyruvate Dehydrogenase Kinase 1.

Journal: ACS nano

Published: December 22, 2025

Physician experience and perceptions of tetrabenazine for the treatment of tardive dyskinesia and Huntington's chorea: a survey of neurologists and psychiatrists.

Physician experience and perceptions of tetrabenazine for the treatment of tardive dyskinesia and Huntington's chorea: a survey of neurologists and psychiatrists.

Journal: Expert review of neurotherapeutics

Published: December 19, 2025

Showing 1-12 of 1,828

Last Updated: 06/30/2026